Analyzing IN8bio (NASDAQ:INAB) & Klotho Neurosciences (NASDAQ:KLTO)

IN8bio (NASDAQ:INAB) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Earnings & Valuation

This table compares IN8bio and Klotho Neurosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01 million	($0.75)	-0.37
Klotho Neurosciences	N/A	N/A	$1.35 million	N/A	N/A

Profitability

This table compares IN8bio and Klotho Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-197.15%	-130.48%
Klotho Neurosciences	N/A	N/A	-25.89%

Institutional & Insider Ownership

92.1% of IN8bio shares are held by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 2.0% of Klotho Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for IN8bio and Klotho Neurosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0	0	2	0	3.00
Klotho Neurosciences	0	0	0	0	0.00

IN8bio presently has a consensus target price of $7.75, indicating a potential upside of 2,718.18%. Given IN8bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Klotho Neurosciences.

Summary

IN8bio beats Klotho Neurosciences on 5 of the 8 factors compared between the two stocks.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.